サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1268937

経口腔粘膜剤の世界市場-2023-2030

Global Oral Transmucosal Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
経口腔粘膜剤の世界市場-2023-2030
出版日: 2023年05月02日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

経口腔粘膜剤の世界市場は、2022年に150億520万米ドルに達し、2030年には244億4,140万米ドルに達することで有利な成長を示すと予測されます。経口腔粘膜剤市場は、予測期間中（2023-2030年）に6.4%のCAGRを示すと予想されています。

世界的に、慢性疾患または非伝染性疾患は増加傾向にあり、全死亡者の73％を占めています。インドでは、非伝染性疾患は、障害調整生存年数の損失の44％、全死亡者の53％の原因となっています。世界の人口の6分の1以上が居住するインドでは、社会経済が大きく開拓され、慢性非伝染性疾患への疫学的傾向が、経口経口薬市場の成長上昇につながりました。

コロナウイルス病2019（COVID-19）の大流行により、特に地域環境において、終末期や緩和ケアのための薬剤の代替投与経路のニーズが急増しています。経粘膜経路には、鼻腔内、頬側、舌下、直腸があります。これらのルートは、自己投与や家族介護による投与が可能で、全身にドラッグデリバリーを行うための非侵襲的なルートです。自己免疫疾患の症例の増加、技術の進歩、市場の開拓などの要因が、世界の経口腔粘膜剤市場の成長を後押ししています。

市場力学

自己免疫疾患やがんの発生率の増加が市場成長を後押しする

例えば、米国がん協会では、毎年、米国における新規がん患者数と死亡者数を推定し、人口ベースのがんの発生と転帰に関する最新データをまとめています。2022年には、米国で1,918,030人の新規がん患者と609,360人のがん死亡者が発生すると予測され、そのうち、がん原因のトップである肺がんによる死亡者は1日あたり約350人とされています。このように、がんの蔓延は市場の成長を後押ししています。

経粘膜薬物の技術的課題

経粘膜ドラッグデリバリーは、非侵襲的であり、自己投与や訓練を受けた介助者による投与が可能なため、経口や非経口の投与形態よりも望ましいとされています。経粘膜投与に適した薬剤を見つけるためには、粘膜薬物吸収のメカニズムを理解することが重要です。鼻腔内粘膜、口腔内粘膜、直腸粘膜はそれぞれ特殊な形態的、生理的特徴を持っているが、いくつかの共通点もあります。

COVID-19の影響分析

サプライチェーンの混乱、政府による封鎖、人手不足、製造活動の制限により、COVID-19のパンデミックは経口経口薬の市場に短期的に悪影響を及ぼしました。一方、経口薬メーカーは、コロナウイルスの流行から、初回通過代謝の低減と作用発現の速さによって利益を得ています。このような性質から、経口経口薬は、緩和ケアや終末期医療において、症状を素早く緩和するのに有用です。状況によっては患者の健康状態が急激に悪化する傾向があるため、COVID-19のパンデミック時には必須となっています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナは、普及率が低く、主要な市場関係者が存在しないため、経口腔粘膜剤の世界市場に与える影響は少ないと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の経口腔粘膜剤市場にほとんど影響を与えないと予測されます。

人工知能の影響分析

人工知能（AI）は、多くの社会分野で普及しており、特に製薬業界では顕著です。人工神経回路網（ANN）、情報技術、無線通信のすべてが、従来の治療法の欠点を克服する可能性を秘めたスマート薬物送達システムの開発に一役買っています。規制された薬物流通のためのデバイスは、無線接続により、より多機能になっています。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲について

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 製品タイプ別スニペット
  • 適応症別スニペット
  • 投与経路別スニペット
  • 流通チャネル別スニペット
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 自己免疫疾患、呼吸器疾患、がんの発生率の増加が市場成長を促進する
      • 薬物療法・薬物療法の使用量の増加について
    • 抑制要因
      • 経粘膜剤に関する規制上の課題
    • 機会
      • 研究開発活動の活発化
    • 影響度分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の解析について
    • COVID-19シナリオ前
    • 現在のCOVID-19シナリオ
    • ポストCOVID-19または将来シナリオ
  • COVID-19 の中での価格ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • 結論

第7章 ロシア・ウクライナ戦争分析

第8章 世界同時不況の分析

第9章 人工知能の影響度分析

第10章 製品タイプ別

  • 錠剤
  • フィルム
  • 液体・スプレー
  • その他

第11章 適応症別

  • オピオイド依存症
  • 神経疾患
  • 勃起不全
  • 吐き気・嘔吐
  • その他

第12章 投与経路別

  • 舌下粘膜
  • 頬粘膜
  • その他

第13章 流通チャネル別

  • 小売薬局
  • 病院内薬局
  • オンライン薬局

第14章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第15章 競合情勢

  • 競合シナリオ
  • 市場シェア分析
  • M&A分析

第16章 企業プロファイル

  • Pfizer Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な展開
  • ZIM Laboratories Limited
  • Aquestive Therapeutics, Inc
  • IntelGenx Corp
  • Indivior PLC
  • C.L.Pharm Co., Ltd
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals, Inc
  • CURE Pharmaceutical.

第17章 付録

目次
Product Code: PH4314

Market Overview

The global oral transmucosal drugs market reached US$ 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 24,441.4 million by 2030. The oral transmucosal drugs market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

Globally, chronic or non-communicable diseases are on the rise and are responsible for 73% of all fatalities. Non-communicable illnesses are to blame for 44% of lost disability-adjusted life years and 53% of all fatalities in India. More than a sixth of the world's people reside in India, which has been experiencing significant socio-economic development and an epidemiological trend towards chronic non-communicable diseases led to the rise in the oral transmucosal drugs market growth.

The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in the need for alternative routes of administration of drugs for end-of-life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. The factors such as growing cases of autoimmune disorders, technological advancements, and oral drugs market developments are boosting the global oral transmucosal drugs market growth.

Market Dynamics

Increase in the incidence of autoimmune disorders and cancer to boost the market growth

For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the U.S., and compiles the most recent data on population-based cancer occurrence and outcomes. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths were projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer. Thus, the prevelance of cancer boost the market growth.

Technical challenges of transmucosal drug

Transmucosal drug delivery is preferable to oral and parenteral forms of administration since it is non-invasive and enables self-administration or administration by trained carers. Understanding the mechanism of mucosal drug absorption is crucial in order to find medications that are right for transmucosal administration. The intranasal, oral, and rectal mucosa each have particular morphological and physiological traits, but they also have several things in common.

COVID-19 Impact Analysis

Due to supply chain disruption, a government-imposed lockdown, manpower shortages, and limitations on manufacturing activities, the COVID-19 pandemic had a short-term detrimental effect on the market for oral transmucosal medications. Oral transmucosal medication producers, on the other hand, are profiting from coronavirus outbreaks by providing reduced first-pass metabolism with a quick onset of action. These qualities make oral transmucosal medications useful for palliative care and end-of-life care to provide quick symptom alleviation. Since some patients' health has a tendency to rapidly decline in some circumstances, it was essential during the COVID-19 pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is anticipated to have little influence over the global oral transmucosal drugs market over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence (AI) has become more prevalent in a number of societal fields, most notably the pharmaceutical industry. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution are more versatile, thanks to wireless connections.

For more details on this report - Request for Sample

Segment Analysis

The global oral transmucosal drugs market is segmented based on product type, indication, route of administartion, distribution channel, and region.

The opioid dependence segment is estimated to hold a majority of the oral transmucosal drugs market share during the forecast period.

The opioid dependence indication holds about 39.6% of the total oral transmucosal drugs market. The growing cases of opioid overdose is driving the segment growth. For instance, according to the World Health Organization 2021, globally about 0.5 million deaths are caused because of drug abuse. Over 70% of these deaths are associated with opioids, accounting for over 30% of those drug overdose deaths.

Moreover, prescribing of opioids in the Canada and U.S. has caused high rates of unacceptable death rates, prescription opioid abuse, and an immense obligation to the affected communities.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global oral transmucosal drugs market during the forecast period.

The Europe region holds the second largest share of the global oral transmucosal drugs market accounting for approximately 29%. The market in the Europe region is being driven by the rising demand for pain management and active regional market participants.

For instance, Aquestive Therapeutics, Inc., a pharmaceutical company that develops drugs to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced in September 2022 that it entered a license and supply agreement for Libervant (diazepam) Buccal Film with Pharmanovia. This agreement will allow Pharmanovia to market Libervant (diazepam) Buccal Film in the European Union, the UK, and other countries.

Competitive Landscape

The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.

Why Purchase the Report?

  • To visualize the global oral transmucosal drugs market segmentation based on product, application, and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global oral transmucosal drugs market report would provide approximately 53 tables, 54figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
      • 4.1.1.2. The increase in medication and pharmacological therapy usage
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory challenges for transmucosal drug
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing number of research and developments activities
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Product Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.1.2. Market Attractiveness Index, By Product Type
  • 10.2. Tablets
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Films
  • 10.4. Liquids & Spray
  • 10.5. Others

11. By Indication

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Opioid Dependence *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Neurological Disorders
  • 11.4. Erectile Dysfunction
  • 11.5. Nausea and Vomiting
  • 11.6. Others

12. By Route of Administration

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.1.2. Market Attractiveness Index, By Route of Administration
  • 12.2. Sublingual Mucosa *
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Buccal Mucosa
  • 12.4. Others

13. By Distribution Channel

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.1.2. Market Attractiveness Index, By Distribution Channel
  • 13.2. Retail Pharmacies*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Hospital Pharmacies
  • 13.4. Online Pharmacies

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Pfizer Inc.*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. ZIM Laboratories Limited
  • 16.3. Aquestive Therapeutics, Inc
  • 16.4. IntelGenx Corp
  • 16.5. Indivior PLC
  • 16.6. C.L.Pharm Co., Ltd
  • 16.7. Seoul Pharmaceuticals
  • 16.8. Shilpa Therapeutics
  • 16.9. Sunovion Pharmaceuticals, Inc
  • 16.10. CURE Pharmaceutical.

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us